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Highlights (for review) 
 
1. We aimed to assess lung fluid balance before and after gradual ascent to 5,150 m; 
2. Lung diffusing capacity increased from sea-level to high-altitude; 
3. Alveolar-capillary membrane conductance also increased from sea-level to high-altitude; 
4. Gradual non-significant reduction in ultrasound lung comets with altitude; 
5. Evidence of a decrease in interstitial lung fluid relative to at sea-level with gradual ascent 
to high-altitude.  
 
Abstract 
We aimed to assess lung fluid balance before and after gradual ascent to 5,150 m. Lung diffusion 
capacity for carbon monoxide (DLCO), alveolar-capillary membrane conductance (DmCO) and 
ultrasound lung comets (ULCs) were assessed in 12 healthy lowlanders at sea-level, and on Day 1, 
Day 5 and Day 9 after arrival at Mount Everest Base Camp (EBC). EBC was reached following an 
8-day hike at progressively increasing altitudes starting at 2,860 m. DLCO was unchanged from 
sea-level to Day 1 at EBC, but increased on Day 5 (11±10%) and Day 9 (10±9%) vs. sea-level 
(30.047). DmCO increased from sea-level to Day 1 (9±6%), Day 5 (12±8%), and Day 9 (17±11%) 
(all P0.001) at EBC. There was no change in ULCs from sea-level to Day 1, Day 5 and Day 9 at 
EBC. These data provide evidence that interstitial lung fluid remains stable or may even decrease 
relative to at sea-level following 8 days of gradual exposure to high-altitude in healthy humans.  
 
Key words: Hypoxia; high-altitude pulmonary edema; lung diffusing capacity; ultrasound lung 
comets.  
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1. Introduction 
7KHYROXPHRIH[WUDYDVFXODUSXOPRQDU\IOXLGLVGHWHUPLQHGE\6WDUOLQJ¶V/DZDQGLVDfunction of 
pulmonary capillary fluid extrusion relative to the rate of fluid reabsorption from the pulmonary 
interstitial compartments (Bates et al., 2011; Butler et al., 1999). Fluid flux across the pulmonary 
vasculature is reflected by the balance between the hydrostatic pressure in the pulmonary capillaries 
and the hydrostatic pressure in the interstitial space, as well as the permeability of the pulmonary 
capillaries to fluid. Fluid clearance or reabsorption from the pulmonary interstitium is largely 
dependent on the activity of the thoracic lymph ducts (Bates et al., 2011) and Na+ transport systems 
located apically on the alveolar surface that actively reabsorb lung fluid that has permeated the 
alveolar-capillary membrane (Matthay et al., 2002; Mutlu et al., 2004).  
 
Exposure to high-altitude is associated with a substantial increase in pulmonary capillary 
hydrostatic pressure due to hypoxic pulmonary vasoconstriction (Maggiorini et al., 2001; Naeije et 
al., 2010), increased pulmonary vascular leakage secondary to endothelial dysfunction (Richalet, 
1995), and inhibition of the epithelial Na2+ transport systems central to lung fluid clearance (Sartori 
et al., 2010). In combination, these changes in the pulmonary system associated with high-altitude 
would be expected to disturb lung fluid balance such that a subclinical increase in interstitial lung 
fluid should occur.  
 
Despite the aforementioned considerations, the evidence for a change in lung fluid balance in 
healthy lowlanders who sojourn at high-altitude remains equivocal (Cogo and Miserocchi, 2011; 
Swenson, 2011), with some but not all reporting a subclinical increase in interstitial lung fluid 
(Agostoni et al., 2013; Bouzat et al., 2013; Cremona et al., 2002; de Bisschop et al., 2012; Dehnert 
et al., 2010; Pratali et al., 2010). It has, however, been suggested that very rapid, acute exposure to 
high-altitude causes a transient, but significant, accumulation of lung fluid (Agostoni et al., 2013; 
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Bouzat et al., 2013; Cremona et al., 2002). For example, Bouzat et al. (Bouzat et al., 2013) reported 
an increase in the number of ultrasound lung comet-tails, a robust index of changes in alveolar-
interstitial fluid (Agricola et al., 2005; Picano and Pellikka, 2016), in healthy subjects transported 
by helicopter to 4,250 m (~10 min). Interestingly, prolonged exposure and gradual adaptation to 
high-altitude appears to be associated with a progressive normalisation (after ~2 weeks) (de 
Bisschop et al., 2012) and subsequent reduction in lung fluid relative to sea-level values (after ~3 
weeks) that may be related to an increase in sympathetic tone (Agostoni et al., 2011). Taken 
together, these previous findings suggest that rapid exposure to high-altitude may facilitate a 
transient, asymptomatic increase in lung fluid in healthy humans that reverses with a period of 
acclimatization, possibly due to a sympathetically mediated upregulation of lung fluid clearance 
mechanisms (Agostoni et al., 2011; Sartori et al., 2002). 
 
However, whether extravascular lung fluid accumulation occurs in healthy, recreational climbers 
gradually exposed to high-altitude (i.e. over 6-10 days) remains uncertain and requires further 
investigation. Accordingly, the aim of the present study was to assess changes in 1) lung diffusing 
capacity and alveolar-capillary membrane conductance, 2) ultrasound lung comets, and 3) 
pulmonary function in healthy lowlanders from before to after gradual exposure to 5,150 m. We 
hypothesised that gradual exposure to high-altitude would not change lung fluid balance relative to 
at sea-level, as evidenced by no change in lung diffusing capacity, alveolar-capillary membrane 
conductance, ultrasound lung comets, and pulmonary function. Importantly, it has been suggested 
that each of these measures provide an accurate index of changes in lung fluid balance (Agostoni 
et al., 2003; Agricola et al., 2005; Cremona et al., 2002; Dehnert et al., 2010; Jambrik et al., 2004; 
Picano and Pellikka, 2016; Snyder et al., 2006). In addition, heart-rate variability was measured as 
an index of autonomic tone before, during and after the expedition.  
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2. Materials and methods 
2.1 Subjects 
Twelve healthy non-smoking adult lowlanders (2 female) with no history of cardiorespiratory or 
metabolic disease participated in the study (mean ± SD; age = 36 ± 11 years, stature = 178 ± 8 cm, 
body mass = 79.7 ± 12.7 NJ7KHVXEMHFWVZHUHSK\VLFDOO\DFWLYH0 min physical activity/day, 
GD\VZHHNVHOI-reported) and had normal forced vital capacity (FVC = 109 ± 12% of predicted), 
forced expiratory volume in 1 s (FEV1 = 103 ± 9 % of predicted), FEV1/FVC ratio (95 ± 7 % of 
predicted) and maximal mid-expiratory flow (MMEF = 106 ± 14% of predicted) at sea-level. Each 
participant gave written informed consent after being provided a detailed description of the study 
requirements. The experimental procedures were approved by the Mayo Clinic Institutional 
Review Board and were performed in accordance with the ethical standards of the Declaration of 
Helsinki. All study participants were prohibited from prophylactic administration of any 
medication to aid altitude acclimatization (e.g., sildenafil, acetazolamide). Moreover, no subject 
required emergent pharmaceutical treatment (e.g., dexamethasone) for high altitude illness.  
 
2.2 Experimental procedures 
Arterial oxygen saturation (SaO2) (via transcutaneous pulse oximetry) and heart-rate (HR) (via 
telemetry) were measured with the participants at rest in the supine position before pulmonary 
function was assessed using a spirometer according to standard procedures (Miller et al., 2005). 
Next, systolic pulmonary artery pressure (sPAP) and the number of ultrasound lung comets (ULCs) 
were obtained using transthoracic sonography. Finally, lung diffusing capacity for carbon 
monoxide and nitric oxide (DLCO and DLNO) were measured. This sequence of measurements 
was performed in each participant at sea-level (Rochester, MN, USA; elevation 401 m), on Day 1 
(within 24 hours), Day 5 and Day 9 after arrival at Mount Everest Base Camp (elevation 5,150 m), 
and within 2 weeks of returning to sea-level after the expedition. To reach Everest Base Camp, 
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each participant travelled to Kathmandu, Nepal (elevation 1,400 m) before being transported by 
airplane to Lukla, Nepal (elevation 2,860 m). From Lukla, the participants completed an 8-day hike 
at progressively increasing altitudes to reach Mount Everest Base Camp. Once at Everest Base 
Camp, the participants were free to move about the camp but were instructed to avoid strenuous 
exercise activities. All meals were served by local support staff and the intake of water was allowed 
ad libitum.   
 
2.3 Pulmonary artery pressure 
sPAP was estimated from the peak velocity of tricuspid regurgitation (TR) using a modified 
Bernoulli equation as described previously (Taylor et al., 2011; Yock and Popp, 1984). With the 
participants in the left lateral supine position, the TR jet was located using 2D-color Doppler 
echocardiography (SonoSite Edge, FUJIFILM SonoSite Inc., Bothell, WA, USA). To determine 
the maximal velocity of the TR jet, the continuous wave sampler was positioned within and parallel 
to the regurgitation jet and sPAP was computed as 4TR2 added to an assumed right atrial pressure 
of 5 mmHg.  
 
2.4 Lung diffusing capacity 
DLCO, DLNO, alveolar-capillary membrane conductance (DmCO) and pulmonary capillary blood 
volume (Vc) were assessed as we have described previously (Coffman et al., 2016b; Taylor et al., 
2016). With subjects in the sitting position, DLCO and DLNO were assessed by simultaneously 
measuring the disappearance of CO and NO via a rapid single breath technique using an automated 
device for performing gaVFDOLEUDWLRQVH[WHPSRUDQHRXVPL[LQJRIJDVHVDQGFDOFXODWLRQV+\S¶DLU
Compact, Medisoft, Dinant, Belgium) (de Bisschop et al., 2012; Pavelescu et al., 2013). For each 
single breath maneuver, the participants were instructed to breathe normally on environmental air 
for 4-5 breaths before exhaling slowly and completely down to residual volume (RV). Once at RV, 
the participants were switched to an inspiratory reservoir filled with 2600 ppm CO, 40 ppm NO, 
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8% He, 21% O2 and N2 balance, and told to inspire rapidly and fully to total lung capacity before 
holding their breath for 4 s. After the breath hold, the participants then exhaled steadily and swiftly 
back to RV. The first 0.9 L of the expired gas was discarded to ensure dead-space wash out with 
the next 0.9 L of the expirate collected for subsequent analysis. The single breath maneuver was 
performed in triplicate at sea-level (pre-expedition), on Day 1, Day 5 and Day 9 after arrival at 
Mount Everest Base  Camp (elevation 5,150 m), and within 2 weeks of returning to sea-level after 
the expedition. Each measure of DLCO and DLNO was separated by four minutes later, according 
to current guidelines (Macintyre et al., 2005).  
 
Following the assessment of lung diffusing capacity, DmCO and Vc were computed as described 
previously (de Bisschop et al., 2012; Glenet et al., 2007; Pavelescu et al., 2013). Based on the 
molecular weight and solubility of CO and NO, the coefficient relating DLNO to DmCO was set at 
1.97 (Aguilaniu et al., 2008) such that DmCO was calculated as the measured DLNO/1.97. Then, to 
solve the Roughton and Forster equation (Roughton and Forster, 1957), 1/ࣄCO was calculated using 
an equation proposed by Forster expressing the blood conductance of CO (i.e. ࣄCO) as a function 
of capillary PO2 (Forster, 1987): 
 
1/ࣄCO = 1.3 + 0.0041 × PcapO2 
 
where PcapO2 is the capillary pressure of O2, estimated as alveolar PO2±9ࡆ 22'/&2îZLWK
SDUWLDOSUHVVXUHVLQPP+J9ࡆ 22 in ml/min, and DLCO in ml/min/mmHg. Based on the measured 
barometric pressure (~400 mmHg) and the expired fraction of O2, the calculated alveolar PO2 at 
Everest Base Camp ranged from 52-60PP+J9ࡆ 22 was calculated using the mass balance of O2 
between inspiration and expiration during the single breath maneuver and DLCO × 1.23 was used 
as a surrogate for DLO2 (Forster, 1987). Using this equation, PcapO2 was calculated at ~116 mmHg 
and ~50 mmHg at sea-level and Everest Base Camp, respectively; these values are similar to those 
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recently reported under similar conditions (de Bisschop et al., 2012). Venous blood was sampled 
for hemoglobin (Hb) concentration and Vc was corrected accordingly for standard concentrations 
of Hb in men (14.6 g/dl) and women (13.4 g/dl) (Macintyre et al., 2005) as measured Vc × (standard 
Hb concentration/measured Hb concentration). To allow comparison between DLCO measured at 
sea-level and high-altitude, DLCO at Everest Base Camp was recalculated using the DmCO and Vc 
values computed at high-altitude and the sea-level (i.e. normoxic) ࣄCO as follows (Pavelescu et al., 
2013): 
 
1/DLCOALT = 1/DmCOALT + 1/ࣄCOSL·VcALT 
 
where, DmCOALT and VcALT are the alveolar-capillary membrane conductance and pulmonary 
capillary blood volume, respectively, calculated at Everest Base Camp using the hypoxic ࣄCO and 
ࣄCOSL is the ࣄCO at sea-level (i.e. the normoxic ࣄCO).  
 
2.5 Ultrasound lung comets 
The number of ULCs was determined via transthoracic sonography, as described previously 
(Bouzat et al., 2013; Picano and Pellikka, 2016). With participants in the supine position, sequential 
examination of 28 intercostal lung fields located at the parasternal, midclavicular, anterior axillary 
and mid-axillary lines from the second to the fourth intercostal space on the left side and from the 
second to the fifth intercostal space on the right side was completed using a portable ultrasound 
(SonoSite Edge, FUJIFILM SonoSite Inc., Bothell, WA, USA) integrated with a cardiac probe. An 
ULC was defined as an echogenic, coherent, wedge-shaped signal that originated from the 
hyperechoic pleural line and extended to the edge of the screen. The presence of an ULC was 
simultaneously verified by two trained operators throughout the study (BT and DS) and the total 
number of ULCs identified was recorded for each participant. 
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2.6 Heart-rate variability 
With subjects at rest and in the supine position, cardiac rhythm was recorded using a custom built 
3-lead ECG during: 1) 5-min of spontaneous breathing, and 2) 5-min of paced breathing (6 
breaths/min). For the paced breathing trial, subjects maintained the respiratory frequency of 6 
breaths/min by following a metronome with distinct inspiratory and expiratory tones. Lead II 
electrocardiograph signals were extracted and recorded at 1000 Hz using a data acquisition system 
(Cardiocap/5, Datex-Ohmeda Inc., Louisville, CO, USA), and beat-by-beat cardiac intervals (RR 
interval) were extracted from the raw electrocardiograph traces during the spontaneous breathing 
and paced breathing trials. Time-domain parameters, namely standard deviation of normal-to-
normal beats (SDNN) and root mean square of successive differences in intervals (RMSSD), were 
derived using custom designed Matlab software (version 7.7.0, The Mathworks Inc., Natick, MA, 
USA) and used to estimate cardiac autonomic activity as previously described (Stewart et al., 
2016). These measures were made in a subset of 8 subjects at sea-level (pre-expedition), on Day 1, 
Day 5 and Day 9 after arrival at Everest Base Camp, and at sea-level within 2 weeks post-
expedition.   
 
2.7 Statistical analyses 
One-way repeated measures ANOVA was used to compare absolute measures of systolic 
pulmonary artery pressure, lung diffusing capacity and related variables (DLCO, DmCO, DmCO/Vc), 
the number of ultrasound lung comets, pulmonary function, and heart rate variability across time 
(sea-level pre-expedition vs. Everest Base Camp Day 1 vs. Everest Base Camp Day 5 vs. Everest 
Base Camp Day 9 vs. sea-level post-expedition). Following significant main effects, planned 
pairwise comparisons were made using the Bonferroni method. The acceptable type I error was set 
at P < 0.05. Data are expressed as group means ± SD. Statistical analyses were performed using 
SPSS version 22.0 for Windows (SPSS, Chicago, IL).  
10 
 
 
3. Results 
3.1 General effects of high altitude 
Overall, exposure to high-altitude was associated with only mild, transient headache and 
fatigue/weakness in our participants. On the morning of Day 1, Day 5, and Day 9 at Everest Base 
Camp, group mean Lake Louise score was not positive for the presence of acute mountain sickness 
(Table 1). From sea-level to high-altitude, there was significant and sustained decrease in resting 
SaO2, and an increase in resting HR and haemoglobin concentration (Table 1).  
 
3.2 Systolic pulmonary artery pressure 
Relative to pre-expedition sea-level values, there was an increase in group mean sPAP on Day 1 
(62 ± 40%, P = 0.001), Day 5 (78 ± 51%, P = 0.001), and Day 9 (64 ± 47%, P = 0.005) at Everest 
Base Camp (Figure 1). Group mean sPAP decreased back to pre-expedition baseline values within 
2 weeks of return to sea-level (Figure 1). 
 
3.3 Lung diffusing capacity 
Group mean and individual subject resting measures of DLCO, DmCO, and DmCO/Vc at sea-level 
(pre- and post-expedition) and at high-altitude are shown in Figure 2. Group mean DLCO was 
unchanged from sea-level pre-expedition to Day 1 at Everest Base Camp (38.3 ± 5.0 vs. 40.5 ± 6.8 
ml/min/mmHg, P = 0.157), but was significantly elevated on Day 5 and Day 9 at Everest Base 
Camp relative to pre-expedition sea-level values (11 ± 10%, P = 0.045 and 10 ± 9%, P = 0.047, 
respectively) (Figure 2). Similarly, group mean DmCO increased from sea-level pre-expedition to 
Day 1 (9 ± 6%, P = 0.003), Day 5 (12 ± 8%, P = 0.003), and Day 9 (17 ± 11%, P = 0.001) at Everest 
Base Camp. In addition, DmCO was greater on Day 9 compared to Day 1 at Everest Base Camp 
(102 ± 12 vs. 96 ± 11 ml/min/mmHg, P = 0.034) (Figure 2). There was no change in group mean 
Vc from sea-level pre-expedition (124 ± 30 ml) to Day 1 (134 ± 34 ml), Day 5 (130 ± 29 ml) and 
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Day 9 (129 ± 29 ml) at Everest Base Camp (all P $FFRUGLQJO\there was an increase in 
group mean DmCO/Vc from sea-level pre-expedition to Day 1 (3 ± 4%), Day 5 (8 ± 12%), and Day 
9 (14 ± 15%) at Everest Base Camp; however, only the change from sea-level to Day 9 was 
statistically significant (P = 0.036) (Figure 2). DLCO, DmCO, and DmCO/Vc returned to pre-
expedition baseline values within 2 weeks of the end of the expedition (Figure 2). 
 
3.4 Ultrasound lung comets 
The total number of ULCs in the right and left lung was normal in each participant at sea-level 
prior to the expedition (mean = 1.9 ± 2.0, range = í6) (Figure 3). Although not statistically 
significant, there was a trend towards a gradual reduction in the number of ULCs from pre-
expedition sea-level values to Day 1, Day 5 and Day 9 at Everest Base Camp (Figure 3). The total 
number of ULCs within 2 weeks after the end of the expedition (1UDQJHí5) were very 
similar to pre-expedition baseline values (Figure 3).  
 
3.5 Pulmonary function 
Group mean FVC, FEV1, FEV1/FVC ratio and MEF25-75% at sea-level (pre- and post-expedition) 
and at high-altitude are shown in Table 2. There was no change in group mean FVC, FEV1, 
FEV1/FVC ratio from sea-level (pre-expedition) to Day 1, Day 5, and Day 9 at Everest Base Camp. 
By contrast, MEF25-75% was greater on Day 5 and Day 9 at Everest Base Camp compared to pre-
expedition sea-level values (10 ± 8%, P = 0.045 and 13 ± 10%, P = 0.026). Additionally, MEF25-
75% was greater on Day 5 compared to Day 1 at Everest Base Camp (P < 0.001) (Table 2). Group 
mean MEF25-75% decreased back to pre-expedition baseline values within 2 weeks of return to sea-
level (Table 2). 
 
3.6 Heart-rate variability 
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Group mean SDNN and RMSSD during spontaneous and paced breathing (6 breaths/min) are 
shown in Table 3. There was a substantial but non-statistically significant reduction in SDNN 
during both spontaneous and paced breathing from pre-expedition sea-level values to Day 1, Day 
5 and Day 9 at Everest Base Camp (Table 3). Similarly, there was a non-significant reduction in 
group mean RMSSD during paced breathing at Day 1, Day 5 and Day 9 at Everest Base Camp 
relative to at sea-level (pre-expedition); no such trend was observed in RMSSD during spontaneous 
breathing (Table 3). Both group mean SDNN and RMSSD during paced breathing were, however, 
significantly lower at sea-level post-expedition compared to at sea-level pre-expedition (P =  0.018 
and P = 0.003, respectively) (Table 3).  
 
4. Discussion 
4.1 Main findings 
In the present study, 12 healthy lowlanders completed an 8-day hike (starting at 2,860 m) at 
progressively increasing altitudes to reach Mount Everest Base Camp (5,150 m), and then stayed 
at this altitude for 10 days before returning to sea-level. The changes in systolic pulmonary artery 
pressure (sPAP), lung diffusing capacity, ultrasound lung comets (ULCs), and pulmonary function 
from sea-level to high-altitude were assessed. In addition, heart-rate variability was measured in 8 
subjects as index of cardiac autonomic activity before, during and after the expedition. The major 
findings were: 1) there was a substantial and sustained increase in sPAP from sea-level to high-
altitude, indicating the presence of hypoxic pulmonary vasoconstriction, 2) lung diffusing capacity 
for carbon monoxide was unchanged from sea-level to Day 1 at Everest Base Camp, but was 
significantly increased on Day 5 and Day 9 relative to pre-expedition sea-level values, 3) alveolar-
capillary membrane conductance (DmCO) increased progressively from sea-level to Day 1, Day 5, 
and Day 9  at Everest Base Camp, with a concomitant increase in the DmCO to pulmonary capillary 
blood volume ratio (DmCO/Vc), 4) there was no change in the number of ULCs from pre-expedition 
sea-level values to Day 1, Day 5 and Day 9 at Everest Base Camp, 5) mid-expiratory flow rate 
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(MMEF25-75%) was greater on Day 5 and Day 9 at Everest Base Camp compared to pre-expedition 
sea-level values; there was no sea-level to high-altitude change in any other measure of pulmonary 
function, and 6) there was a substantial but non-statistically significant reduction in SDNN 
(spontaneous and paced breathing) and RMSSD (paced breathing only) from pre-expedition sea-
level values to Day 1, Day 5 and Day 9 at Everest Base Camp. In combination, these data provide 
evidence that interstitial lung fluid remains stable, and may even decrease slightly, relative to sea-
level values following just 8 days of gradual exposure to high-altitude in healthy humans. Although 
somewhat speculative, it is possible that a hypoxia-mediated increase in sympathetic tone is the 
primary cause of this reduction in lung fluid at high-altitude. 
 
4.2 Technical considerations 
4.2.1 The use of indirect measures of interstitial lung fluid  
One concern is that measures of lung diffusing capacity and ULCs provide only an indirect measure 
of lung fluid balance. However, it has been shown that a short term decrease in DLCO is consistent 
with an increase in extravascular lung water, particularly if the reduction in DLCO is primarily 
mediated by a decrease in gas conductance across the alveolar-capillary membrane (i.e. DmCO) 
(Agostoni et al., 2003). Indeed, previous data from our laboratory demonstrated a significant 
increase in CT derived measures of lung fluid with a concomitant decrease in DmCO following 
experimentally-induced pulmonary oedema in healthy humans (Snyder et al., 2006).  
 
µ%-OLQHV¶RU8/&Vare thought to originate from reflections of discrete air/fluid interfaces between 
collapsed, fluid-filled, and well aerated alveoli. It is suggested that the appearance of ULCs likely 
corresponds to a progressive loss of air per volume of lung tissue with a concomitant increase in 
relative and absolute content of extravascular lung water (Picano and Pellikka, 2016). However, it 
is also possible that an increase in the number of ULCs in response to alveolar hypoxia or high-
altitude may simply represent an increase in thoracic lymph flow that is required to prevent 
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interstitial fluid accumulation (Levine et al., 1988). Additionally, the lack of a strong correlation 
between ULCs and pulmonary vascular pressures and other indirect indices of a shift in lung fluid 
balance, including clinical congestion score and lung volumes, may question the utility of this 
measure. Despite these concerns, it has been reported previously that the number of ULCs 
correlates well with lung wet/dry ratio in animals and radiologic lung water score in humans, 
suggesting that the presence of ULCs is indeed a robust measure of changes in interstitial lung fluid  
(Agricola et al., 2005; Jambrik et al., 2010; Jambrik et al., 2004; Picano and Pellikka, 2016). 
 
Based on the aforementioned considerations, it appears that the measures of lung diffusing 
capacity, especially DmCO, and ULCs used in the present study provide an accurate index of 
changes in lung fluid balance. Accordingly, we are confident in our conclusion that lung fluid 
volume remains stable, and may even decrease slightly, relative to sea-level values in healthy 
humans gradually acclimatised to high-altitude.  
 
4.2.2 $VVXPSWLRQWKDWșNO is infinite 
We have addressed the considerations regarding the use of a defined ࣄNO value (i.e. 4.5 
ml/min/mmHg) in previous publications (Coffman et al., 2016a; Coffman et al., 2016b; Taylor et 
al., 2016). While the use of this specific finite ࣄNO in the calculation of DmCO and Vc has recently 
been recommended (Zavorsky et al., 2017), we believe this remains a matter of debate for several 
reasons. Although it has been estimated that 37% of the resistance to NO uptake lies in the 
1/ࣄNO·Vc component (Borland et al., 2014; Borland et al., 2010), it has been argued that application 
of this figure in the whole body human must be treated with caution as its calculation involved 
exchange transfusion in dogs, substituting bovine Hb-glutamer 200 for whole blood (Hughes and 
van der Lee, 2013). Additionally, it has also been estimated that DLNO would not need to be 
adjusted unless the hemoglobin concentration is <8 g/dl (Borland et al., 2010). Thus, it can be 
postulated that if the overall binding or mass transfer of NO to hemoglobin is not affected by a 
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substantial lowering of Hb concentration (until lower than 8 g/dL), then the resistance proposed to 
be provided by the red blood cell to NO (i.e. ࣄNO) would not have any major physiological effect 
on the measurement of alveolar-capillary membrane conductance. Accordingly, there is currently 
no consensus on the application of the assumption of a finite value for ࣄNO in the calculation of 
DmCO and Vc in humans. Furthermore, in our experience, application of a finite ࣄNO of 4.5 
ml/min/mmHg typically results in DmCO values that are excessively large and do not compare 
favorably to values previously reported in whole body humans (de Bisschop et al., 2012).  As such, 
in the present manuscript we calculate DmCO and Vc based on the assumption that ࣄNO is infinite.  
 
4.3 Changes in lung fluid balance with hypoxia and at high-altitude: comparison to previous 
studies 
Exposure to high-altitude is associated with a hypoxia-mediated increase in pulmonary capillary 
hydrostatic pressure (Maggiorini et al., 2001; Naeije et al., 2010) as well as an increase in 
pulmonary vascular leakage (Richalet, 1995) and an inhibition of the epithelial Na2+ transport 
systems central to lung fluid clearance (Sartori et al., 2010). Theoretically, these changes may 
conspire to disturb lung fluid balance such that an increase in interstitial lung fluid would occur at 
high-altitude. However, despite the aforementioned considerations, the evidence for a change in 
lung fluid balance in healthy lowlanders who sojourn at high-altitude remains equivocal (Cogo and 
Miserocchi, 2011; Swenson, 2011).  
 
While cases of overt high-altitude pulmonary oedema (HAPE) are somewhat rare (Hackett et al., 
1976; Maggiorini et al., 1990), it has been suggested by some that subclinical interstitial pulmonary 
oedema is far more prevalent in lowlanders rapidly exposed to high-altitude (Agostoni et al., 2013; 
Bouzat et al., 2013; Cremona et al., 2002; Pratali et al., 2010). For example, Cremona et al. 
(Cremona et al., 2002) reported a ~25% increase in closing volume, thought to be indicative of 
airway compression secondary to peribronchial cuffs of fluid, in ~75% of climbers who ascended 
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from 1,200 m to 4,559 m in ~24 hours. Similarly, Agostoni et al. (Agostoni et al., 2013) found a 
significant reduction in alveolar-capillary membrane conductance (DmCO) (~5.4 ± 7.4 
ml/min/mmHg), which is thought to consistent with an increase in extravascular lung water, in 
healthy lowlanders who climbed to 4,559 m in < 36 hours. Conversely, Dehnert et al. (Dehnert et 
al., 2010) reported no change in total lung capacity, forced vital capacity, closing volume and lung 
compliance from low- to high-altitude in healthy humans who climbed to 4,559 m in < 24 hours. It 
must be stressed, however, that subjects with evidence of mild alveolar edema on chest radiographs 
did experience minor decreases in forced vital capacity, diffusing capacity and lung compliance 
and minor increases in closing volume (Dehnert et al., 2010), perhaps questioning the sensitivity 
of lung function tests for the detection of very mild interstitial pulmonary fluid accumulation. 
Taken together, the aforementioned findings suggest that rapid, acute exposure to high-altitude 
causes a small, asymptomatic accumulation of interstitial lung fluid in otherwise healthy humans, 
although does remain a matter of debate (Cogo and Miserocchi, 2011; Swenson, 2011). 
 
By contrast, it has been shown that short-term exposure to normobaric hypoxia has no effect on 
lung wet weight or may even decrease lung fluid in healthy animals and humans (Aarseth et al., 
1980; Aarseth and Karlsen, 1977; Aarseth et al., 1975; Snyder et al., 2006). For example, Aarseth 
and Karlsen reported a rapid and marked reduction in both pulmonary blood volume and 
extravascular water content in rats exposed to 10% O2 (Aarseth and Karlsen, 1977). Similarly, a 
17-hour exposure to ~12.5% O2 decreased lung tissue volume (approximately í150 ml) and 
extravascular lung water (approximately í75 ml) in healthy adult humans (Snyder et al., 2006). 
While we and others have previously suggested that lung fluid regulation may be different in 
response to normobaric vs. hypobaric hypoxia (Girard et al., 2012), it does appear that prolonged 
exposure and subsequent gradual adaptation to high-altitude is accompanied by normalisation and 
perhaps even a reduction in lung fluid relative to sea-level values in humans (Agostoni et al., 2011; 
de Bisschop et al., 2012). For example, Agostoni et al. (Agostoni et al., 2011) assessed DLCO, 
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DmCO and Vc in 33 healthy lowlanders at sea-level and again after a 9 day trek to followed by a 2 
week residence at 5,400 m. The authors reported that, relative to sea-level, there was a ~1.5 
ml/min/mmHg and a ~39.0 ml/min/mmHg increase in DLCO and DmCO, respectively, following 3 
weeks at high-altitude despite a ~60% increase in pulmonary artery systolic pressure. These 
increases were paralleled with a significant rise in plasma epinephrine concentration, which is 
suggestive of an increase in sympathetic tone (Agostoni et al., 2011). These data suggest that 
gradual, prolonged exposure to high-altitude (~3 weeks) results in a decrease in interstitial lung 
fluid that may, at least in part, be mediated by an upregulation of fluid clearance mechanisms 
secondary to an increase in sympathetic drive. Presently, we found that a slow ascent and gradual 
adaptation to high-altitude caused a significant increase in DLCO (~10-11%) and DmCO (~9-17%) 
along with no change in the number of ultrasound lung comets relative to sea-level in 12 healthy 
lowlanders. In the present study, however, the aforementioned changes, which are indicative of a 
reduction in interstitial lung fluid, were apparent on Day 1 at Everest Base Camp; that is, after only 
8 days at high-altitude. These changes occurred despite a substantial and sustained increase in sPAP 
from sea-level to high-altitude (~68%) and were coincident with a substantial, but non-significant, 
decrease in SDNN and RMSSD, which is suggestive of a decrease in cardiac parasympathetic tone. 
Based on the current findings, we postulate that a sympathetically mediated stimulation of the beta-
2 adrenergic system facilitates clearance or reabsorption of interstitial lung fluid at a rate greater 
than fluid extrusion of the pulmonary capillaries secondary to significant hypoxic pulmonary 
vasoconstriction, even after only 8 days of gradual adaptation to high-altitude.        
 
4.4 Potential mechanisms by which lung fluid is cleared at high-altitude 
A reduction in interstitial lung fluid, and the associated increase in DLCO and gas conductance 
across the alveolar-capillary membrane (i.e. increased DmCO), in healthy lowlanders gradually 
acclimatised to high-altitude likely serves to improve alveolar-capillary PO2 equilibration and thus 
minimise the reduction SaO2 that accompanies exposure to high-altitude. In addition, the potential 
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importance of an increase in DLCO and DmCO LQEHWWHUPDLQWDLQLQJ9ࡆ 22max at high-altitude was 
demonstrated by Wagner (Wagner, 1996). UVLQJDWKHRUHWLFDOQXPHULFDODQDO\VLVRIWKHLQIOXHQFH
RIWKHOXQJVFLUFXODWLRQDQGPXVFOHVRQ9ࡆ 22max, the author reported that neither the fall in maximal 
cardiac output nor the increase in haemoglobin concentration associated with chronic hypoxia 
affected 9ࡆ 22max. By contrast, with increasing altitude there was a progressive increase in the 
influence of lung diffusion capaciW\ RQ 9ࡆ 22max, with high values of lung diffusing capacity 
appearing to be advantageous for exercise at high-altitude (Wagner, 1996).   
 
There are several mechanisms by which gradual acclimatization to high-altitude may have resulted 
in a decrease in interstitial lung fluid volume in our subjects in the present study. Based on the 
following evidence, we suggest that the reduction in extravascular lung water associated with 
gradual adaptation to high-DOWLWXGH LQ WKH SUHVHQW VWXG\ ZDV GXH WR DFWLYDWLRQ RI WKH ȕ2-ARs 
secondary to a large hypoxia-mediated increase in sympathetic drive. It is likely that stimulation of 
beta-2 adrenergic receptors (ȕ2-ARs) secondary to sympathetic activation at high-altitude improved 
IOXLG FOHDUDQFH IURP WKH SXOPRQDU\ LQWHUVWLWLXP 7KH ȕ2-ARs are expressed throughout the 
pulmonary system, including in the airways, the alveolar spaces, the pulmonary vasculature and 
the pulmonary lymphatic tissue, and stimulation of these receptors activates Na2+ transport systems 
located apically on the alveolar surface that act to reabsorb lung fluid that has permeated the 
alveolar-capillary barrier (Matthay et al., 2002; Mutlu et al., 2004). In addition, it has been shown 
WKDW VWLPXODWLRQ RI WKH ȕ2-ARs on lymphatic tissue causes dilation as well as active phasic 
contraction of the thoracic lymphatic ducts, which acts to clear lung fluid from the perivascular 
spaces to the hilar lymph nodes (Ikomi et al., 1991; Mahe et al., 1991). Moreover, ȕ2-AR 
stimulation appears to tighten the cell-to-cell contacts within the vascular endothelium, which in 
turn would be expected to decrease pulmonary capillary permeability and reduce fluid flux into the 
lung interstitial space (Allen and Coleman, 1995). )LQDOO\DGPLQLVWUDWLRQRIWKHORQJDFWLQJȕ2-AR 
agonist salmeterol resulted in a ~50% decrease in the incidence of high-altitude pulmonary oedema 
19 
 
(HAPE) in HAPE susceptible but otherwise healthy humans (Sartori et al., 2002). It must be 
stressed, however, that owing WR WKHPXOWLSOHDFWLRQVRIȕ2-AR agonists, including inhibition of 
hypoxic pulmonary vasoconstriction and upregulation of NO production, whether the prevention 
of HAPE was as a direct result of enhanced lung fluid clearance remains uncertain (Bartsch and 
Mairbaurl, 2002).    
 
4.5 Conclusions 
In conclusion, gradual adaptation to high-altitude may cause a decrease in interstitial lung fluid 
volume in healthy lowlanders, as evidenced by an increase in lung diffusing capacity for carbon 
monoxide and alveolar-capillary membrane conductance, and a trend towards a reduction in the 
number of ultrasound lung comets. This decrease in extravascular lung water was observed as early 
as after ~8 days of high-altitude exposure. Although somewhat speculative, we propose that a 
hypoxia-mediated activation of tKHȕ2-AR system, which is critical in the regulation of lung fluid, 
is the likely cause of this reduction in lung fluid in healthy lowlanders at high-altitude. 
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Figure legends 
Figure 1. Group mean ± SD (panel A) and individual subject (panel B) systolic pulmonary artery 
pressure (sPAP) at sea-level prior to the expedition (Sea-Level Pre), after 1 day, 5 days and 9 days 
at Mount Everest Base-camp (EBC Day 1, EBC Day 5 and EBC Day 9), and within 2 weeks of 
returning back to sea-level after the expedition (Sea-Level Post). *P < 0.05, value significantly 
different vs. Sea-Level Pre-H[SHGLWLRQP < 0.05, value significantly different vs. Sea-Level Post-
expedition.  
 
Figure 2. Group mean ± SD and individual subject lung diffusing capacity for carbon monoxide 
(DLCO) (panels A and B), alveolar-capillary membrane conductance (DmCO) (panels C and D), 
and the ratio of DmCO to pulmonary capillary blood volume (Vc) (panels E and F) at sea-level prior 
to the expedition (Sea-Level Pre), after 1 day, 5 days and 9 days at Mount Everest Base-camp (EBC 
Day 1, EBC Day 5 and EBC Day 9), and within 2 weeks of returning back to sea-level after the 
expedition (Sea-Level Post). *P < 0.05, value significantly different vs. Sea-Level Pre-expedition; 
P < 0.05, value significantly different vs. Sea-Level Post-expedition; #P < 0.05, value 
significantly different vs. EBC Day 1. 
 
Figure 3. Group mean ± SD (panel A) and individual subject (panel B) changes in the number of 
ultrasound lung comets (ULCs) at sea-level prior to the expedition (Sea-Level Pre), after 1 day, 5 
days and 9 days at Mount Everest Base-camp (EBC Day 1, EBC Day 5 and EBC Day 9), and within 
2 weeks of returning back to sea-level after the expedition (Sea-Level Post).  
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Table 1. Effect of high-altitude on Lake Louise score, haemoglobin concentration, arterial oxygen saturation & resting heart-rate 
 
Sea-Level 
Pre-expedition 
Everest Base-camp 
Day 1 
Everest Base-camp 
Day 5 
Everest Base-camp 
Day 9 
Sea-Level 
Post-expedition 
LLS  í  2.1 ± 1.4 1.7 ± 1.0 1.3 ± 0.9  í  
[Hb], g/dL 15.4 ± 1.0 17.3 ± 1.1* 17.4 ± 1.1 17.4 ± 1.0 15.5 ± 1.0 
SaO2, % 97 ± 1 82 ± 4 84 ± 4 85 ± 6 98 ± 3 
HR, bpm 68 ± 15 80 ± 10 81 ± 13 77 ± 9* 72 ± 12 
Values are group means ± SD for 12 subjects (2 female). LLS, Lake Louise score; [Hb], haemoglobin concentration; SaO2, estimated arterial oxygen 
saturation; HR, resting heart-rate. *P < 0.05, value significantly different vs. Sea-Level Pre-H[SHGLWLRQP < 0.05, value significantly different vs. Sea-Level Post-
expedition.   
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Table 2. Lung function variables at sea-level (before and after the expedition) and at high-altitude 
 
Sea-Level 
Pre-expedition 
Everest Base-camp 
Day 1 
Everest Base-camp 
Day 5 
Everest Base-camp 
Day 9 
Sea-Level 
Post-expedition 
FVC, L 5.72 ± 0.72 5.72 ± 0.68 5.75 ± 0.68 5.74 ± 0.75 5.63 ± 0.84 
FEV1, L 4.38 ± 0.42 4.45 ± 0.44 4.50 ± 0.37 4.51 ± 0.48 4.40 ± 0.47 
FEV1/FVC, % 77.0 ± 6.5 78.2 ± 6.5 78.9 ± 7.0 79.0 ± 6.3 78.7 ± 6.2 
MEF25-75%, L/s 4.40 ± 0.66 4.74 ± 0.82 4.82 ± 0.85* 4.91 ± 0.59* 4.45 ± 0.82 
Values are group means ± SD for 12 subjects (2 female). FVC, forced vital capacity; FEV1, forced expiratory volume in 1 s; MEF25-75%, maximum mid-
expiratory flow. *P < 0.05, value significantly different vs. Sea-Level Pre-H[SHGLWLRQP < 0.05, value significantly different vs. Sea-Level Post-expedition; #P < 
0.05, value significantly different vs. Everest Base-camp Day 1.  
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Table 3. Heart-rate variability parameters during spontaneous and paced breathing at sea-level (before and after the expedition) and at high-altitude 
 
Sea-Level 
Pre-expedition 
Everest Base-camp 
Day 1 
Everest Base-camp 
Day 5 
Everest Base-camp 
Day 9 
Sea-Level 
Post-expedition 
 Spontaneous breathing 
SDNN, ms 51.9 ± 34.3 39.7 ± 24.7 39.7 ± 14.5 36.0 ± 18.9 42.3 ± 23.9 
RMSSD, ms 67.5 ± 22.0 64.1 ± 19.0 67.2 ± 14.6 58.2 ± 17.7 73.9 ± 31.1 
 Paced breathing (6 breaths/min) 
SDNN, ms 68.8 ± 39.6 52.5 ± 21.2 39.0 ± 18.7 48.3 ± 21.3 48.8 ± 22.3* 
RMSSD, ms 100.4 ± 31.6 94.5 ± 26.4 82.4 ± 23.9 82.1 ± 29.5 81.0 ± 29.1* 
Values are group means ± SD for 8 subjects (0 female). SDNN, standard deviation of normal-to-normal beats; RMSSD, root mean square of successive 
differences in intervals. *P < 0.05, value significantly different vs. Sea-Level Pre-expedition. 
 
 
 
 
 
 
 
 
 
 
